journal of bioequivalence & bioavailability mistry and ... · mistry p, menon s (2013)...

Volume 5(5): 215-223 (2013) - 215J Bioequiv AvailabISSN:0975-0851 JBB, an open access journal

Research Article Open Access

Mistry and Menon, J Bioequiv Availab 2013, 5:4 DOI: 10.4172/jbb.1000161

Research Article Open Access

*Corresponding author: Paresh Mistry, Accutest Research Laboratories (I) Pvt. Ltd, S.G. Highway, Ahmedabad-380054, Gujarat, India, Tel: 91-982-568-1583, E-mail: [email protected]

Received May 07, 2013; Accepted August 22, 2013; Published August 31, 2013

Citation: Mistry P, Menon S (2013) Haemolysis Effect Estimation of Doxycycline Hyclate 150 mg Delay Release Tablet in Bio-analysis (Human Plasma) by Liquid Chromatography-Tandem Mass Spectrometry. J Bioequiv Availab 5: 215-223. doi:10.4172/jbb.1000161

Copyright: © 2013 Mistry P, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

AbstractA fast, simple and particular method for estimation of Doxycycline in healthy human plasma was validated using Minocycline as IS. The analyte and IS were extracted from plasma using SPE. The compound was estranged on a RP column with an isocratic mobile phase consisting of 0.1% formic acid in water and acetonitrile (12:88, v/v), and detected by tandem mass spectrometry in positive ion mode. The ion transition recorded in several reaction monitoring mode were m/z 294.1→225.1 for Doxycycline and m/z 286.1→217.1 for IS. Linearity in plasma was observed over the concentration range 0.3-30 ng/mL for Doxycycline. The mean recovery for Doxycycline was 83.7%, with a lower limit of quantification of 0.3 ng/mL. The coefficient of variation of the assay was less than 6.8%, and accuracy of 96.1% to 102.2%. The validated method was applied to bioequivalence study of 150 mg Doxycycline Hyclate tablet in healthy human volunteers. The validated method was used to expose study samples of bioequivalence study of 150 mg Doxycycline Hyclate delay release tablet in 36 healthy human volunteers. Total 50 samples from individual volunteers identified as Haemolyzed, which were analyze initial and repeat again to cross check the method reproducibity for Haeamolysis effect and compared which found acceptable range. Bioequivalence was prove for test and reference using validated method to experimental samples (Figure 1).

Haemolysis Effect Estimation of Doxycycline Hyclate 150 mg Delay Release Tablet in Bio-analysis (Human Plasma) by Liquid Chromatography-Tandem Mass SpectrometryParesh Mistry1,2* and Shobhna Menon1

1School of Sciences, Chemistry Department, Gujarat University, Ahmedabad, Gujarat, India 2Accutest Research Laboratories (I) Pvt. Ltd, S.G. Highway, Ahmedabad-380054, India

Keywords: Doxycycline hyclate; Minocycline; LC-MS-MS; Humanplasma

IntroductionIn BA/BE studies, Haemolysis effect can be responsible for analysis

of drug estimation in plasma. Validation of LC-MS/MS assays includes an assessment of hemolytic effects though the experiment. Recognition of this effect in attendance of drug can be supportive tool for estimation of assay in plasma. Validated method is used to evaluate Haemolysis effect can simply prove the impact on drug estimation. Validation of drug estimation can be challenged through the Haemolysis samples which are unknown though Incurred sample reanalysis to compare the method ruggedness, with respect to Haemolysis sample which are extracted directly from subjects (volunteers).

Tactic was applied to reduce Haemolysis effect through proper extraction techniques like SPE. We establish method with proper extraction techniques to reduce the Haemolysis effect, and then challenge our method in subject analysis, specifically for Haemolysis samples along with normal plasma samples [1].

Summarize the assay value for combination drugs for Haemolysis samples and through Incurred subject reanalysis cross check the techniques used for validation is properly applied as per regulation described in USFDA guidance [2].

Doxycycline Hyclate (Delayed-Release Tablet) contains particularly coated pellets of Doxycycline hyclate, a broad-spectrum antibiotic synthetically derived from oxytetracycline, in a delayed-release formulation for oral administration (Figure 1).

Molecular prescription of Doxycycline Hyclate is (C22H24N2O8·HCl)2·C2H6O·H2O and a molecular weight of 512.94. Doxycycline hyclate is a yellow crystalline soluble powder in water and in solutions of alkali hydroxides and carbonates. Doxycycline has a high degree of lipid solubility and a low affinity for calcium binding. It is highly stable in normal human serum.

It is used in malaria. It should not be used alone for initial cure of malaria. This delay is related to its mechanism of action, it is also used for the treatment of Rickettsial infections, sexually transmitted infections, Respiratory tract infections, Specific bacterial infections, ophthalmic infections, Anthrax, including inhalational anthrax (Post- Exposure) [3].

Quantitative Analysis of Quinine and Doxycycline in Formulations was reported through LC-MS method. It was carried out on a Sun Fire Waters C18 column and the mobile phase consisted of acetonitrile: 0.1% formic acid (75:25, v/v), run at a flow rate of 0.45 mL/min (split 1:3). The injection volume was 10 µL for both standard and samples.

Figure 1: Structure of doxycycline hyclate.

Journal of B ioequivalence & Bioavailability Jo

urna

l of B

ioequivalence & Bioavailability

ISSN: 0975-0851

http://www.rxlist.com/script/main/art.asp?articlekey=8121

http://www.rxlist.com/script/main/art.asp?articlekey=23369

http://en.wikipedia.org/wiki/Malaria


J Bioequiv AvailabISSN:0975-0851 JBB, an open access journal Volume 5(5): 215-223 (2013) - 216

The triple quadruple mass spectrometer equipped with an electro spray source in positive mode (ES+) was set up in Multiple Reactions Monitoring mode (MRM), monitoring the transitions of 325.0>307.0 and 445.0>428.1, for quinine and Doxycycline, respectively [4].

In another reported method, Quantitative Analysis of Doxycycline in Healthy Human Plasma was done through LCMS/MS. Method was developed and validated for the determination of Doxycycline in plasma for a range of 1.0 ng/mL to 200 ng/mL Demeclocycline was used as the IS. The analytes in plasma were extracted by acetonitrile protein precipitation. HPLC conditions included a Phenomenex Columbus C18 2.0×50 mm column utilizing a gradient operation with water and acetonitrile [5].

LC/MS Method for the fortitude of Doxycycline in Human EDTA K3 Plasma was also reported. Doxycycline and its IS were extracted from EDTA K3 plasma by PPT. Analysis was done on an Agilent MSD GL 1100 Series single mass spectrometer using Electro spray interface. Positive ions were measured using SIM with m/z 445.20 for Doxycycline. The chromatography was achieved on an X-Terra C18 MS column, with a run time of 4.6 minutes per sample. This method used two mobile phases, which are a mixture of trifluoroacetic acid and acetonitrile. This assay was validated at a nominal range of 4 to 400 ng/mL [6].

RP-HPLC method also published with fluorescence detection was optimized and validated for determination of Doxycycline in human saliva and Gingival Crevicular Fluid (GCF) with tetracycline as IS. Single step extraction with acetonitrile for both types of samples was performed. The separation was achieved at Zorbax Extend-C18 analytical column at 30oC. Mobile phase was consisted of an aqueous phase containing magnesium acetate, ammonium acetate, Na2 EDTA, triethyl-ammonium acetate buffered to pH 7.5 with ammonium hydroxide solution and acetonitrile. The volume ratio of the buffered water mixture of salts and acetonitrile was 86:14. Fluorescence detector was set at λex=380 nm and λem=520 nm. This method was successfully applied for Doxycycline in saliva and GCF obtained from patients with chronic periodontal disease [7].

Method was established and validated to verify Doxycycline in human plasma using SPE technique, which give good analysis in terms of number of samples daily and give proper selectivity and recovery. For the method, IS was used as Minocycline.

Experimental ProcedureTotal number of 26 samples of different time points has been

collected with individual subjects in each period. Blood samples will be collected in Na-Heparin Vaccutainer. All the blood samples will be centrifuged under refrigeration with the machine set at, RPM, 10 minutes and 5°C. Plasma samples will be placed in deep freezer maintained at -20°C ± 5°C. Total number of 50 samples was identified as

Haemolyzed samples. The Haemolyzed samples were initially analyzed and results were collected as initial concentration. The same samples were again analyzed to cross check method reproducibility in terms of Haemolysis effect in plasma as incurred subject reanalysis. Overall subjects concentration were reported and analyzed to demonstrate the Bioequivalence of test and reference product of Doxycycline 150 mg DR Tablet for the design of two way cross over, two periods for test and reference product.

Materials and chemicals

Reference standards of Doxycycline and Minocycline were obtained from Sun Pharmaceuticals Industries Ltd. (Baroda, India). These standards had purity ≥ 99%. HPLC grade methanol and acetonitrile were purchased from J.T. Baker INC (Phillipsburg, NJ, USA). Formic acid of AR grade was procured from Merck Ltd (Mumbai, India). (Phenomenex Strata-X (30 mg/1 mL) SPE cartridges were procured from Orochem India Pvt. Ltd., (Mumbai, India). Water used in the entire analysis was prepared through Milli-Q water purification system from Millipore (Bangalore, India). Na Heparin plasma was collected through volunteer’s drug free blood.

Liquid chromatography and mass spectrometric conditions: The liquid chromatography system coupled with mass spectrometer (API, SCIX) consisted of Shimadzu/LC-20 AD Prominence, auto sampler and temperature controlled compartment for column. The analytical column, Chromolith RP18e (100 mm×4.6 mm) was used for separation of analyte and IS. Mobile phase of 0.5% (v/v) Formic Acid in Water was pumped isocratically at flow rate of 1 mL/min. Auto sampler temperature was set at 4°C and the injection volume was 5 µL. The column oven temperature was maintained at 40°C and the Retention time is 1.29 min and 1.27 for Doxycycline and Minocycline, respectively [8].

The Applied Biosystems/API 2000 LC-MS-MS apparatus was operated at unit resolution in the multiple reaction monitoring (MRM) mode, monitoring the transition of the protonated molecular ion m/z 445.0 to the product ion m/z 428.1 for Doxycycline, and the transition of the protonated molecular ion m/z 458.2 to the product ion m/z 441.1 for the IS, Minocycline (Table 1 and Figures 2 and 3). The instrument response was optimized for Doxycycline and Minocycline by infusing a constant flow of a solution of the drug dissolved in mobile phase. Electro Spray Ionization (ESI) was performed in the positive ion mode. The instrument was interfaced with a computer running Analyst Version 1.4.2.

Preparation of standards and quality control samples: Two separate stock solutions of Doxycycline were prepared for bulk spiking of CC and QC samples for the MV test as well as the subject sample analysis. A 1 mg/mL stock solution for Doxycycline and Minocycline were organized by dissolving their exactly weighted compounds in methanol. This stock solution of Doxycycline thus prepared was

Drug Scan type Q1 mass (amu)

Q3 mass (amu)

Dwell time (msec)

Compound parameters (V)DP FP CE CXP EP

Doxycycline MRM 445.1 428.1 200 25.0 400.0 26.0 12.5 5.5

Minocycline MRM 458.2 441.1 200 20.0 400.0 25.0 13.0 7.0

Source Parameters

Ion Spray Voltage CUR GAS 1 GAS 2 Temperature CAD GAS

3000 V 22 35 75 400°C 3

Table 1: Mass parameters and source parameter.



Figure 2: Product ion mass spectra of Doxycycline.

Figure 3: Product ion mass spectra of Minocycline.



serially diluted to prepare working solution in required concentration range with diluents methanol: water (70:30, v/v). The calibration standards and Quality Control (QC) samples were prepared by spiking (5% of the total plasma volume) with working solutions. Calibration standards were prepared at concentration of 50.000, 100.000, 250.000, 500.000, 1250.000, 2000.000, 3000.000, 4000.000, and 5000.000 ng/mL for Doxycycline. Similarly, Quality Control standards (QC’s) were prepared at four different concentrations namely, 51.000 (LLOQ QC), 140.000 (LQC), 2250.000 (MQC) and 3750.000 (HQC) ng/mL. Enough calibration standards and quality control standards were prepared to validate the method, and to serve as standards and controls during the assay of all study samples. However, during the study, only three levels of controls were prepared as LQC (Lower Quality Control), MQC (Middle Quality Control) and HQC (Higher Quality Control). Aliquots of the standards and quality controls were stored together with the study samples at -20°C, until used for sample processing.

Extraction method

The plasma samples (200 µl) were transferred to 1.7 mL clear tubes (Tarsons, India) and added 25 µl of IS (working solution of 40.000 µg/mL of Minocycline). The samples were vortexed. 0.200 mL of 0.5% (v/v) Formic Acid in water was added in each tube, followed by vortexing for 30 second. Tubes were centrifuged at 14000 RPM at 10°C for 5 minutes. Conditioning and equilibration of SPE cartridge (Phenomenex Strata-X (30 mg/1 mL) was done by passing 1 mL Methanol, followed by 1 mL of Water. Than plasma samples were load on the cartridges. Cartridges were washing with 1 mL of 5% (v/v) Methanol in Water twice. Samples were eluted by passing 1 mL of Elution Solution. Samples were centrifuged at 14000 rpm at 10°C for 5 minutes. Samples were transferred into auto sample vials.

Method ValidationSelectivity

Selectivity was performed using 10 different sources of blank plasma comprising of 6 normal, two Haemolyzed and two lipemic. They were processed as per the extraction method, and their response was assessed at the retention time of analytes, and the IS with six LLOQ samples for Doxycycline were prepared from the screened blank plasma samples which had the least interference [9].

Carry over

Carryover effect was evaluated to ensure that the rinsing solution used to clean the injection needle and port is able to avoid any carry forward of injected sample in subsequent runs. The design of the experiment comprised blank plasma, LLOQ, Upper Limit of Quantitation (ULOQ), followed by blank plasma to check for any possible interference due to carryover.

Linearity and lower limit of quantification

The linearity of the method was determined by analysis of five standard plots associated with a nine-point standard calibration curve. The ratio of area response for analyte to IS was used for regression analysis. Each calibration curve was analyzed individually by using least square weighted (1/x2) linear regression. The calculation was based on the peak area ratio of analyte versus the area of IS. The concentration of the analyte were calculated from calibration curve (y=mx+c; where y is the peak area ratio), using linear regression analysis with reciprocate of the drug concentration as a weighing factor (1/x2). Several regression types were tested and the linear regression (weighted

with 1/concentration2) was found to be the simplest regression, giving the best results (r2 ≥ 0.9985). The lowest standard on the calibration curve was accepted as the lower limit of quantitation (LLOQ), if the analyte response was at least five times more than that of drug free (blank) extracted plasma. The deviation of standards other than LLOQ from the nominal concentration should not be more than ± 15.0% for LLOQ, it should not be more than ± 20.0%.

Accuracy and precision

The intra-batch and inter-batch accuracy and precision were determined by replicate analysis of the four quality control levels on three different days. In each of the precision and accuracy batches, six replicates at each quality control level were analyzed. Mean and Standard Deviation (SD) were obtained for calculated drug concentration over these batches. Accuracy and precision were calculated in terms of Relative Error (%RE) and Coefficient of Variation (% CV), respectively.

Matrix effect

The assessment of matrix effect (co-eluting, undetected endogenous matrix compounds that may influence the analyte ionization) was performed by processing six lots of different normal controlled plasma samples in replicate (n=4). LQC and HQC working solutions were spiked post extraction in duplicate for each lot. The results found were well within the acceptable limit set, i.e. the RSD of area ratio to be within ± 15% at each level tested. Also, the ion suppression/enhancement of analyte signal due to endogenous matrix interferences does not affect the quantification of analyte and IS peak which was confirmed by post-column infusion experiment. A standard solution containing Doxycycline (at MQC level) and IS was infused post column via a ‘T’ connector into the mobile phase at 10 µL/min employing in-built infusion pump. Aliquots of 5 µL of extracted control plasma were then injected into the column by the auto sampler and MRM LC-MS/MS chromatogram was acquired for analytes. Any dip in the baseline upon injection of double blank plasma (without IS) would indicate ion suppression, while a peak at the retention time of analyte would indicate ion enhancement.

Recovery

Absolute recoveries of the analyte were determined at the three different quality control levels viz. LQC, MQC and HQC, by comparing the peak areas of the extracted plasma samples with those of the unextracted standard mixtures (prepared in the elution solution at the same concentrations as the extracted samples), representing 100% recovery.

Dilution integrity

The dilution integrity experiment was intended to validate the dilution test to be carried out on higher analyte concentrations (above ULOQ), which may be encountered during real subject samples analysis. It was performed at 1.6 times the ULOQ concentration. Six replicates samples of ½ and ¼th concentration were prepared and their concentrations were calculated by applying the dilution factor of 2 and 4, respectively, against the freshly prepared calibration curve.

Stability

All stability results were evaluated by measuring the area response (analyte/IS) of stability samples against comparison samples of identical concentration. Stock solutions of Doxycycline and IS were



checked for short term stability at room temperature and long term stability at 2-8°C. The solutions were considered stable if the deviation from nominal value was within ± 10.0%. Bench top stability, auto sampler stability (process stability), freeze thaw stability and long-term stability in plasma were performed at LQC and HQC level using six replicates at each level. Freeze-thaw stability was evaluated by successive cycles of freezing (at -20°C) and thawing (without warming) at room temperature. To meet the acceptance criteria, the difference between the stability and fresh samples should be within ± 15%.

The same method was applied for pharmacokinetic study as A Randomized, Open Label, Balanced, Two-Treatment, Four-Period, Two-Sequence, Replicate, Crossover, Single Dose, Bioequivalence Study of Doxycycline 150 mg delay release tablet in Normal, Healthy,

Adult, Human Subjects Under Fasting Condition to evaluated bioequivalence.

Results and DiscussionThe mean absolute recoveries of Doxycycline determined at

140.000, 2250.000 and 3750.000 ng/mL were 78.05 (RSD 5.00%), 75.42 (RSD 0.51%) and 77.21% (RSD 2.01%), respectively. The mean absolute recovery of Minocycline was 97.44 %( RSD 1.64%). Minimal matrix effect for Doxycycline was observed from the six different plasma lots tested. The RSD of the area ratios of post spiked recovery samples at LQC and HQC levels were less than 2.62% for Doxycycline. For the IS, the RSD of the area ratios over both LQC and HQC levels was less than 3.57%. This indicated that the extracts were “clean”, with no co-eluting

S. No. Run IDBack calculated concentration (ng/mL)

LLOQ QC LQC MQC HQCNominal 51.000 140.000 2250.000 3750.000

1 1_PA01_DI01

52.054 135.890 2138.233 3894.28554.541 147.006 2143.167 3655.23152.213 132.561 2277.448 3602.05750.892 144.378 2163.433 3753.03155.299 135.245 2234.456 3671.56651.913 145.184 2201.595 3703.162

Mean 52.819 140.044 2193.055 3713.222SD 1.709 6.164 55.283 101.907% CV 3.24 4.40 2.52 2.74% Accuracy 103.57 100.03 97.47 99.02N 6 6 6 6

A: Intra day precision and accuracy of doxycycline

Sr. No. Run IDBack calculated concentration (ng/mL)

LLOQ QC LQC MQC HQCNominal 51.000 140.000 2250.000 3750.000

1 2_PA01_DI01

52.054 135.890 2138.233 3894.28554.541 147.006 2143.167 3655.23152.213 132.561 2277.448 3602.05750.892 144.378 2163.433 3753.03155.299 135.245 2234.456 3671.56651.913 145.184 2201.595 3703.162

2 3_PA02_ABSOLUTE RECOVERY

55.405 137.067 2247.117 3606.68354.149 143.092 2316.983 3601.44853.430 140.503 2172.055 3740.80150.001 142.142 2188.159 3601.12651.115 137.198 2062.007 3651.58551.173 137.447 2155.949 3515.588

3 4_PA03

45.613 131.408 2076.568 3638.90351.750 131.422 2125.969 4044.55847.921 131.279 2320.304 3616.17047.615 137.615 2097.308 3607.01949.777 134.943 2113.591 3958.92948.176 127.819 2141.915 3785.726

Mean 51.280 137.344 2176.459 3702.659SD 2.758 5.442 76.688 139.659% CV 5.38 3.96 3.52 3.77% Accuracy 100.55 98.10 96.73 98.74N 18 18 18 18

B: Inter day precision and accuracy of doxycycline

Table 2: Intra day and inter day precision and accuracy of doxycycline.



compounds influencing the ionization of the analyte and the IS.

The high selectivity of MS-MS detection allowed the development of a very specific and rapid method for the determination of Doxycycline in plasma. No significant interfering peak of endogenous compounds was observed at the retention time of analyte in blank human plasma containing Na Heparin as the anti-coagulant in ten different plasma lots which was compared versus six replicates of extracted samples at the LLOQ level.

The LLOQ, defined as that concentration of Doxycycline, which can still be determined with acceptable precision (%RSD ≤ 20) and accuracy (bias within ± 20%) was found to be 50.000 ng/mL. Results of the intra-batch and inter-batch validation assays are presented in Table 2, respectively. The inter-batch and intra-batch precision were ≤ 5.38% and ≤ 4.40%, whereas the inter-batch and intra-batch accuracy in terms of % bias were within the range of -3.27 to 0.55 and -2.53 to 3.57 for Doxycycline, respectively.

Bench top and processed (auto sampler) stability for Doxycycline were performed at LQC and HQC levels. The results revealed that Doxycycline was stable in plasma for at least 15 h at room temperature and 49 h in auto sampler at 10°C. It was confirmed that repeated freeze and thawing (five cycles) of spiked plasma samples at LQC and HQC level did not affect the stability of Doxycycline. Doxycycline was found stable for minimum five freeze and thaw cycles. The long term stability results also indicated that Doxycycline was stable in human plasma for up to 96 days at a storage temperature of -20°C & -70°C. This period of long term stability was sufficient enough to cover the entire storage period from first day of storage of the plasma samples to the last day of analysis.

During method development, different options were evaluated to optimize sample extraction, detection parameters and chromatography. Electro spray ionization (ESI) was evaluated to get better response of analytes, as compared to Atmospheric Pressure Chemical Ionization (APCI) mode. In the nonionic forms, the strong binding of analytes to the copolymer of SPE cartridge enables sufficient clean up. Best signal for the analyte was achieved with the ESI positive ion mode. The effect of pH of buffer also checked on sensitivity and peak shape. But, the best signal and peak shape for Doxycycline was achieved using a mobile phase of 0.05% (v/v) formic acid in deionised water. Use of a short Chromolith RP18e (100 mm×4.6 mm) column resulted in reduced flow rate 1 mL/min with Splitter, 60% flow to waste and reduced run time. The retention times for Doxycycline and Minocycline were ~ 1.29 minutes and ~ 1.27 minutes, respectively.

Minocycline, used as IS, belonged to the same therapeutic category as Doxycycline. Ionization, retention and extraction characteristics were found to be similar to that of Doxycycline, and hence, it was selected as the IS of choice. The validated method was employed to analyze plasma samples containing Doxycycline obtained from a single oral dose of 150 mg Doxycycline per treatment in 36 healthy volunteers under fasting conditions. Blank sample, spike sample (CS1) and subject sample chromatogram with IS are presented (Figure 4a and 4b). The study design was a randomized, open label, Two-treatment, two-sequence, two-period, crossover, single dose, bioequivalence study. The study conducted was carried out after approval from an independent ethics committee and obtaining written consent from the volunteers.

Test vs. reference product of Doxycycline 150 mg Delayed release

To be continued...



Figure 4: a. Chromatogram of blank check. b. Chromatogram of spike sample.



tablet result, as shown in Table 3, detailed that the both the product meets bioequivalence.

ConclusionA simple, selective and rapid method for the estimation of

Doxycycline in human plasma was developed and validated, using LCMS/MS API 2000. The validated method was used in a

bioequivalence study in which 36 healthy volunteers were enrolled; each subject dosed 150 mg Doxycycline tablets (reference and test) as a single oral dose. The method allows higher sample throughput due to the short chromatography and simple sample preparation. Robust LC-MS-MS performance was observed, with acceptable variation in instrument response within batches. This method is an excellent analytical option for rapid quantification of Doxycycline in human

Sr. No. Sample I.D Initial Conc. (ng/mL) (A) Repeat Conc.(ng/mL) (B) Mean C:(A+B)/2 % Diff1 01 / I / 006 3450.686 3349.363 3400.025 -2.982 01 / I / 009 3494.588 3412.553 3453.571 -2.383 01 / I / 020 740.183 728.439 734.311 -1.604 01 / I / 021 316.661 346.565 331.613 9.025 01 / II / 009 3132.694 3334.969 3233.832 6.256 01 / II / 010 3018.738 3389.569 3204.154 11.577 01 / II / 021 314.951 353.057 334.004 11.418 01 / II / 022 153.357 147.811 150.584 -3.689 02 / I / 006 2302.093 2695.926 2499.010 15.7610 02 / I / 007 2325.019 2542.780 2433.900 8.9511 02 / I / 019 654.602 651.265 652.934 -0.5112 02 / I / 020 268.152 296.138 282.145 9.9213 02 / II / 005 2570.680 2708.345 2639.513 5.2214 02 / II / 006 2408.683 2537.141 2472.912 5.1915 02 / II / 019 687.463 715.645 701.554 4.0216 02 / II / 020 335.565 361.391 348.478 7.4117 03 / I / 008 3572.916 3365.365 3469.141 -5.9818 03 / I / 012 3242.747 3420.542 3331.645 5.3419 03 / I / 021 468.291 491.968 480.130 4.9320 03 / I / 022 214.316 213.116 213.716 -0.5621 03 / II / 006 3924.709 3100.400 3512.555 -23.4722 03 / II / 007 4518.131 3891.392 4204.762 -14.9123 03 / II / 022 249.541 209.604 229.573 -17.4024 03 / II / 023 163.996 128.357 146.177 -24.3825 04 / I / 007 3335.021 3321.079 3328.050 -0.4226 04 / I / 011 3339.249 3507.108 3423.179 4.9027 04 / I / 019 1072.730 1158.220 1115.475 7.6628 04 / I / 020 381.138 400.302 390.720 4.9029 04 / II / 009 2032.321 2302.294 2167.308 12.4630 04 / II / 012 2079.133 1994.308 2036.721 -4.1631 04 / II / 019 662.633 789.707 726.170 17.5032 04 / II / 020 277.824 321.136 299.480 14.4633 05 / I / 007 2817.893 2854.185 2836.039 1.2834 05 / I / 008 2740.465 2691.639 2716.052 -1.8035 05 / I / 020 388.346 373.503 380.925 -3.9036 05 / I / 021 187.789 187.384 187.587 -0.2237 05 / II / 010 2213.004 2535.508 2374.256 13.5838 05 / II / 011 2210.087 2186.241 2198.164 -1.0839 05 / II / 020 567.237 565.742 566.490 -0.2640 05 / II / 021 179.722 187.670 183.696 4.3341 06 / I / 011 3248.921 3607.874 3428.398 10.4742 06 / I / 012 3009.303 2865.491 2937.397 -4.9043 06 / I / 020 440.952 426.658 433.805 -3.3044 06 / I / 021 175.673 157.904 166.789 -10.6545 06 / II / 011 3508.409 3167.121 3337.765 -10.2346 06 / II / 013 3462.987 3653.528 3558.258 5.3547 06 / II / 020 448.842 459.760 454.301 2.4048 06 / II / 021 189.901 178.460 184.181 -6.2149 07 / I / 008 2950.533 2797.557 2874.045 -5.3250 07 / I / 010 2915.308 2782.023 2848.666 -4.68

Sample ID xx/yy/zz whereas xx denotes Subject number; yy: Period number; ZZ: Time point number.Table 3: Incurred subject reanalysis result of Haemolysis samples for Doxycycline.



plasma. Result shown in Table 4, with initial run while Sample Analysis compare with Incurred subject re analysis to demonstrate method reproducibility as 96% ISR samples meet acceptance criteria for Erythromycin Ethylsuccinate, whereas the acceptance criteria for ISR is 67% samples should meet + or - 20% difference. The test and reference formulation behavior was resulted as bioequivalence.References

1. Krishna AC, Sathiyaraj M, Saravanan RS, Chelladurai R, Vignesh R (2012) A novel and rapid method to determine doxycycline in human plasma by liquid chromatography tandem mass spectrometry. Indian J Pharm Sci 74: 541-548.

2. (2001) Guidance for Industry, Bioanalytical Method Validation, U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CVM).

3. h t t p : / / w w w . u s p . o r g / s i t e s / d e f a u l t / f i l e s / u s p _ p d f / E N / U S P N F /doxycyclineHyclateTablets.pdf

Analyte Treatment Cmax(ng/mL) Tmax AUCt AUCinf Kel T1/2(h)

DoxycyclineTest 3323.86 3.10 75168.89 77838.59 0.03 19.63

Reference 3493.27 3.02 80037.67 82619.92 0.03 19.42

Table 4: Summary of statistics for target parameters, Test vs. Reference, following a single dose of Doxycycline 150 mg Delay release tablet to thirty six volunteers under fasting conditions.

4. Junior LB, Uchoab FT, Guterresab SS, Costaab TD (2009) Development and validation of LC-MS/MS method for the simultaneous determination of quinine and doxycycline in pharmaceutical formulations. J Liquid Chromat Relat Technol. 32: 2699-2711.

5. http://www.aapsj.org/abstracts/AM_2000/2749.htm

6. http:// www.aapsj.org/ abstracts/Am_2003/ AAPS2003-000711.pdf

7. Denic MS, Sunaric SM, Kesic LG, Minic IZ, Obradovic RR, et al. (2013) RP-HPLC assay of doxycycline in human saliva and gingival crevicular fluid in patients with chronic periodontal disease. J Pharm Biomed Anal 78-79: 170-5.

8. (2010) Quantitative analyses of four antibiotics in plasma by liquid chromatography-tandem mass spectrometry.

9. Guo L, Chen Y, Zhang L, Yang W, He P (2012) Development and validation of a liquid chromatographic/ tandem mass spectrometric method for determination of chlortetracycline, oxytetracycline, tetracycline, and doxycycline in animal feeds. J AOAC Int 95: 1010-1015.

http://www.ncbi.nlm.nih.gov/pubmed/23798780



http://www.usp.org/sites/default/files/usp_pdf/EN/USPNF/doxycyclineHyclateTablets.pdf

http://www.usp.org/sites/default/files/usp_pdf/EN/USPNF/doxycyclineHyclateTablets.pdf

http://www.tandfonline.com/doi/abs/10.1080/10826070903245805#.UidRJW1OdLM











journal of bioequivalence & bioavailability mistry and ... · mistry p, menon s (2013)...

Documents